*** Live: Wednesday, November 11, 2020 | 8:30 AM EDT – 4:00 PM EDT *** 2020 Bio/Pharma Virtual Congress: Join Pharmaceutical Technology® and BioPharm International® for this online event that will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry. ***On demand available after final airing until 11/11/2021***
Recent trends in data analytics highlight the use of modeling techniques to improve process control and monitoring in biopharmaceutical production.
The Lucullus process information management system facilitates bioprocess development and optimization by centralizing data management and control of multiple BR1000 bioreactor systems that each employ dynamic PAT-driven glucose feeding
In part 2 of this article, results from the testing of a next generation convecdiff membrane are discussed.
How can liquid drug substances be safety stored and transported between downstream and fill/finish processes?
Bio/pharma can learn ways to prevent recurring events and ineffective CAPA from the nuclear power sector.
Bringing promising ADC candidates to market faster hinges on the biopharma industry investing in linker design capabilities.
FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Sufficient stability studies show a drug product meets regulatory requirements, therefore ensuring the drug reaches the patients who rely on it.
Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency.
March 17th 2022 at 10am EST | 9am CST | 3pm GMT | 4pm CET • Automating and Streamlining MS-Based Developability Assessment of Biotherapeutics• Automating MS-Based Biotherapeutic Characterization Workflows for Developability
A best practices approach to pharma’s most challenging-to-inspect container.
Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.
Leveraging smart technology and SMEs for significant operational and financial benefits.
The biopharmaceutical landscape of India is transforming in terms of regulatory policies, product development, and affordability.
Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.
This article presents the results of a survey conducted to gain insight on the impact of the COVID-19 pandemic on biomanufacturing operations.
The development of an innovative purification process simplifies downstream processing for biologics.
Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.
Modular and replication strategies are being utilized to meet growing demand for CDMO facilities.
Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.
A series of minute virus of mice spiking studies were performed with a monoclonal antibody product and small-scale AEX membrane adsorbers to evaluate a range of critical processing conditions.